- Home
- VRCA vs DTIL Comparison
VRCA vs DTIL Comparison
Compare VRCA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- DTIL
- Stock Information
- Founded
- VRCA 2013
- DTIL 2006
- Country
- VRCA United States
- DTIL United States
- Employees
- VRCA N/A
- DTIL N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- DTIL Health Care
- Exchange
- VRCA Nasdaq
- DTIL Nasdaq
- Market Cap
- VRCA 58.7M
- DTIL 55.3M
- IPO Year
- VRCA 2018
- DTIL 2019
- Fundamental
- Price
- VRCA $4.75
- DTIL $4.61
- Analyst Decision
- VRCA Hold
- DTIL Strong Buy
- Analyst Count
- VRCA 5
- DTIL 2
- Target Price
- VRCA $60.00
- DTIL $47.00
- AVG Volume (30 Days)
- VRCA 36.2K
- DTIL 78.0K
- Earning Date
- VRCA 11-03-2025
- DTIL 11-03-2025
- Dividend Yield
- VRCA N/A
- DTIL N/A
- EPS Growth
- VRCA N/A
- DTIL N/A
- EPS
- VRCA N/A
- DTIL N/A
- Revenue
- VRCA $14,704,000.00
- DTIL $1,261,000.00
- Revenue This Year
- VRCA $264.34
- DTIL N/A
- Revenue Next Year
- VRCA $33.95
- DTIL $135.19
- P/E Ratio
- VRCA N/A
- DTIL N/A
- Revenue Growth
- VRCA 5.72
- DTIL N/A
- 52 Week Low
- VRCA $3.82
- DTIL $3.61
- 52 Week High
- VRCA $20.60
- DTIL $10.71
- Technical
- Relative Strength Index (RSI)
- VRCA 31.51
- DTIL 40.75
- Support Level
- VRCA $4.87
- DTIL $4.86
- Resistance Level
- VRCA $5.20
- DTIL $5.17
- Average True Range (ATR)
- VRCA 0.36
- DTIL 0.24
- MACD
- VRCA -0.04
- DTIL -0.03
- Stochastic Oscillator
- VRCA 0.57
- DTIL 16.18
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.